dna vaccine and biopharmaceutical protein production
DESCRIPTION
DNA vaccine and Biopharmaceutical protein Production. Theerapol Sirinarumitr DVM, Ph.D. Department of Pathology, Faculty of Veterinary Medicine Kasetsart University. Transcription. Transcription. Translation. Translation. Background. Prokaryotes. Eukaryotes. HISTORY. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/1.jpg)
DNA vaccine and DNA vaccine and Biopharmaceutical Biopharmaceutical
protein protein ProductionProduction
Theerapol Sirinarumitr DVM, P Theerapol Sirinarumitr DVM, Ph.D.h.D.
Department of Pathology, Fac Department of Pathology, Fac ulty of Veterinary Medicine ulty of Veterinary Medicine
Kasetsart University Kasetsart University
![Page 2: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/2.jpg)
Background
TranscriptionTranscrip
tion
Translation
Translation
Prokaryotes Eukaryotes
![Page 3: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/3.jpg)
![Page 4: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/4.jpg)
![Page 5: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/5.jpg)
![Page 6: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/6.jpg)
![Page 7: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/7.jpg)
![Page 8: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/8.jpg)
![Page 9: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/9.jpg)
![Page 10: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/10.jpg)
![Page 11: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/11.jpg)
![Page 12: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/12.jpg)
![Page 13: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/13.jpg)
![Page 14: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/14.jpg)
![Page 15: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/15.jpg)
![Page 16: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/16.jpg)
![Page 17: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/17.jpg)
![Page 18: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/18.jpg)
![Page 19: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/19.jpg)
![Page 20: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/20.jpg)
![Page 21: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/21.jpg)
![Page 22: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/22.jpg)
![Page 23: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/23.jpg)
![Page 24: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/24.jpg)
HISTORYHISTORY
• Skeletal muscle cell can u Skeletal muscle cell can u ptake naked DNA (plasmi ptake naked DNA (plasmi
d carried genes) and expr d carried genes) and expr essed those genes essed those genes (Scienc(Scienc
-e 2 4 7 :1 4 6 5 1 4 6 -e 2 4 7 :1 4 6 5 1 4 6 8 1990, by Wolff et al.) 8 1990, by Wolff et al.)
![Page 25: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/25.jpg)
AdvantagesAdvantages
• Readily delivery Readily delivery• Molecularly defined reagent Molecularly defined reagent• Neither infectious nor capab Neither infectious nor capab
le of replication le of replication• Elicited both humoral and ce Elicited both humoral and ce
- ll mediated immune respons- ll mediated immune responsee
![Page 26: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/26.jpg)
AdvantagesAdvantages• Manipulate the resulting immune r Manipulate the resulting immune r
- esponse through the co deliverly o - esponse through the co deliverly o f genes encoding immunodulating f genes encoding immunodulating
cytokines or costimulatory molecu cytokines or costimulatory moleculesles
• - site directed mutagenesis for enh- site directed mutagenesis for enh ancing antigenic potency of indivi ancing antigenic potency of indivi
dual epitope or to abolish unwante dual epitope or to abolish unwante - d effects of wild type protein - d effects of wild type protein
![Page 27: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/27.jpg)
![Page 28: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/28.jpg)
Purpose of Purpose of vaccinationvaccination
•ProphylaxisProphylaxis•TherapeuticTherapeutic
– infectious agentinfectious agent– cancercancer
![Page 29: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/29.jpg)
Gene delivery and Gene delivery and ExpressionExpression
• Routes of administration Routes of administration– epidermal, mucosal, intra epidermal, mucosal, intra
muscular and intravenous muscular and intravenous
• Skeletal muscle and skin Skeletal muscle and skin (Langerhans cell) (Langerhans cell)
• Plasmid DNA persisted e Plasmid DNA persisted e pisomally in myocytes pisomally in myocytes
![Page 30: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/30.jpg)
![Page 31: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/31.jpg)
• Intramuscular injection and pa Intramuscular injection and pa- rticle mediated delivery of plas- rticle mediated delivery of plas
mid DNA mid DNA• - Particle mediated delivery req- Particle mediated delivery req
uired up to 5000 times less DN uired up to 5000 times less DN A than intramuscular or intrad A than intramuscular or intrad
ermal inoculation of DNA (nano ermal inoculation of DNA (nano - gram vs 25 100 microgram) - gram vs 25 100 microgram)
![Page 32: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/32.jpg)
• Transfection efficiency does not Transfection efficiency does not necessarily correlate with the ef necessarily correlate with the ef
ficiency of immunization ficiency of immunization• Intradermal injection (low trans Intradermal injection (low trans
fection efficiency) can elicit pot fection efficiency) can elicit pot ent immune response when co ent immune response when co
mpared to muscle (higher trans mpared to muscle (higher trans fection efficiency) fection efficiency)
![Page 33: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/33.jpg)
•Site and method of DNA Site and method of DNA delivery may affect the nature delivery may affect the nature of the immune response of the immune response (skeletal muscle and skin)(skeletal muscle and skin)
LC and keratinocyte LC and keratinocyte
Take up and Take up and process antigenprocess antigen
Proinflammatory cytokines: Proinflammatory cytokines: - - -1IL , TNF a & GM CSF- - -1IL , TNF a & GM CSF
Muscle can notMuscle can not
* Dendritic cell * Dendritic cell LL**10 LL**10
![Page 34: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/34.jpg)
![Page 35: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/35.jpg)
• ID or IMinjection induce Th ID or IMinjection induce Th 1 bias of the immune respo 1 bias of the immune respo
- - nse INF G producing CD - - nse INF G producing CD 4 + IgG2 a isotype 4 + IgG2 a isotype
• Genegun(skinor muscl e) i nduces i mmun Genegun(skinor muscl e) i nduces i mmun e responses with Th2 bias e responses with Th2 bias
![Page 36: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/36.jpg)
![Page 37: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/37.jpg)
![Page 38: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/38.jpg)
Muscle controlMuscle controlMuscle uptakeMuscle uptake
![Page 39: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/39.jpg)
DNA vaccine’s DNA vaccine’s immunologyimmunology
![Page 40: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/40.jpg)
Processing and Processing and PresentationPresentation
(8-12 amino acids)(8-12 amino acids)
![Page 41: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/41.jpg)
12-25 amino acid12-25 amino acid
![Page 42: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/42.jpg)
![Page 43: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/43.jpg)
•Protein-based vaccine Protein-based vaccine elicitation of elicitation of strong CTLstrong CTL
![Page 44: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/44.jpg)
![Page 45: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/45.jpg)
![Page 46: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/46.jpg)
• Th1-type Th1-type responsesresponses– CD8+ CTLCD8+ CTL– CD4+ Th1 cellsCD4+ Th1 cells– IgG2a>IgG1IgG2a>IgG1– IFN-g>IL-4,IL-IFN-g>IL-4,IL-
5,IL-105,IL-10– IL-2, IL-12IL-2, IL-12
• Th2-type Th2-type responsesresponses– DTHDTH– IL-4 and IL-IL-4 and IL-
1010
![Page 47: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/47.jpg)
![Page 48: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/48.jpg)
• Influenza,rabies,HIV,HBV,HCV&HSV Influenza,rabies,HIV,HBV,HCV&HSV• Mycobacterium tuberculo Mycobacterium tuberculo
sis, Mycoplasma pulmoni sis, Mycoplasma pulmoni s, and Borrelia burgdorfer s, and Borrelia burgdorfer
ii• Mal ari a andLei shmani a Mal ari a andLei shmani a
anmlinfc.htm
![Page 49: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/49.jpg)
Genetic Genetic engineering of engineering of
immune responseimmune response
![Page 50: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/50.jpg)
Engineering Engineering Immune ResponseImmune Response
• Costimulatory molecule Costimulatory molecule• Immunostimulatory cyto Immunostimulatory cyto
kinekine• Immunostimulatory DNA Immunostimulatory DNA
sequences (ISS) sequences (ISS)• Biological adjuvant Biological adjuvant
![Page 51: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/51.jpg)
Costimulatory mole Costimulatory moleculescules
•B7.1 (CD28)B7.1 (CD28)•B7.2B7.2•CD40 (CD40L)CD40 (CD40L)
Enhance T-cell responseEnhance T-cell responseapoptosisapoptosis
![Page 52: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/52.jpg)
Immunostimulatory Immunostimulatorycytokinescytokines
• - T cell growth factors- T cell growth factors– - LL-L2 & 7- LL-L2 & 7
• - Th 1 biasing cytokines - Th 1 biasing cytokines– - -12IFN a and IL- -12IFN a and IL
![Page 53: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/53.jpg)
Immunomodulatory molecules Immunomodulatory molecules EffectEffect A. Cytokine proteins A. Cytokine proteins
-1IL-1IL Antibody (Ab) Antibody (Ab)-2IL-2IL AbAb-12IL-12IL Th1 (DTH) Th1 (DTH)LLL -LLLL -L Ab, DTH Ab, DTHL L -L LLL L -L LL AbAb
![Page 54: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/54.jpg)
B. Expression plasmids B. Expression plasmids-IL 1 2-IL 1 2 CTL (i.m. & i.n .) CTL (i.m. & i.n .)
DTHDTHAbAb
-GM CSF-GM CSF AbAbCTLCTL
TCA3TCA3 CTL CTLDTHDTHAbAb
-B7 1-B7 1 CTLCTLDTHDTHAbAb
![Page 55: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/55.jpg)
-72B -72B CTLCTLDTHDTHAbAb
CD40(L)CD40(L) AbAbCTLCTL
![Page 56: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/56.jpg)
![Page 57: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/57.jpg)
Immunostimulatory Immunostimulatory DNA sequences DNA sequences
• Unmethylated CpG dinucleotide Unmethylated CpG dinucleotidemotiffmotiff– In mammal DNA, CpG is suppressed by In mammal DNA, CpG is suppressed by
2 0 fold (bacteria and virus DNA= 1 2 0 fold (bacteria and virus DNA= 1/1 6 )/1 6 )
– - stimulateinnatei mmune system(non speci fi c anti mi - stimulateinnatei mmune system(non speci fi c anti mi crobialsystem) crobialsystem)
– sensi ti ze the speci fi c i mmune syst sensi ti ze the speci fi c i mmune syst embothanti body andcel l medi atedi embothanti body andcel l medi atedi
mmune response mmune response
![Page 58: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/58.jpg)
– 1Th bias of immune respo 1Th bias of immune respo - nse IFN g producing C - nse IFN g producing C
L LLLLL LLL LLLLLLLLL L 4 L LLLLL LLL LLLLLLLLL L 4
cellcell– Cis and Trans effect Cis and Trans effect– - - - - -1 6INF a/b, IFN g, TNF a, IL , IL- - - - -1 6INF a/b, IFN g, TNF a, IL , IL
- -, IL 12, IL 18 - -, IL 12, IL 18
![Page 59: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/59.jpg)
• - 12Type I interferons and IL - 12Type I interferons and IL LLLLLLLL LLLLLLLLLLLL LL L L LLLLLLLL LLLLLLLLLLLL LL L L
cells, CD8 + CTL cells, CD8 + CTL• - ’ () (., 199 7) - ’ () (., 199 7)• ISS can eliminate severe adver ISS can eliminate severe adver
se effects of Freund’s adjuvant se effects of Freund’s adjuvant
![Page 60: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/60.jpg)
• at least one CpG (near terminal m at least one CpG (near terminal m uch less effective) uch less effective)
• - Methylation at C 5 position of the - Methylation at C 5 position of thecytosinecytosine
• Poly (dG, dC) activate macrop Poly (dG, dC) activate macrop hage and NK cell and stimulate an hage and NK cell and stimulate an
-tiviral response (IFN a/b) -tiviral response (IFN a/b)• Phosphorothioate modified ODNs Phosphorothioate modified ODNs
- - (ps ODNs) show 200 fold more po- - (ps ODNs) show 200 fold more po tent than Phosphodiester ODNs ( tent than Phosphodiester ODNs (
-po ODNs)-po ODNs)
![Page 61: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/61.jpg)
IFN-g
- -5 ’ pu pu C - -5 ’ pu pu C- - G py py 3’- - G py py 3’
G A G A T T T T
CC
Optimal B cell activationOptimal B cell activation
IL-18IL-18
Class I MHCClass I MHCCD40CD40ICAM-1ICAM-1CD16/32CD16/32
(IgM)(IgM)IL-12
CD40, CD16/32CD40, CD16/32ICAM-1ICAM-1APCAPC
![Page 62: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/62.jpg)
ChloroquineChloroquineTLR-6TLR-6
![Page 63: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/63.jpg)
![Page 64: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/64.jpg)
• DNAvaccine can elicitboth h DNAvaccine can elicitboth h umoral and cellular immune r umoral and cellular immune r
esponse (biolistic Th 2 esponse (biolistic Th 2bias)bias)
• - - Th 1 biasing cytokines (IFN a - - Th 1 biasing cytokines (IFN a - or IL 1 2 ) shiftbiolistic - or IL 1 2 ) shiftbiolistic
cutaneousi mmune response toTh1 cutaneousi mmune response toTh1
![Page 65: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/65.jpg)
• Side effects Side effects– - - -Provocationofasepticshockl i ke syndrome (I L 1,TNF a - - -Provocationofasepticshockl i ke syndrome (I L 1,TNF a
-LL, ) -LL, )– LLLLLL L LLLLL LLLLLLLL L( LLLLLL L LLLLL LLLLLLLL L(
ather than ISS) ather than ISS)• - - -neutrophils, TNF a, IL 6 , MIP - - -neutrophils, TNF a, IL 6 , MIP
2 significantdamage 2 significantdamage
![Page 66: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/66.jpg)
– Autoimmune disease Autoimmune disease• some evidence of bacterial DNA some evidence of bacterial DNA
-SLE (high IL 6 ) -SLE (high IL 6 )• certaintypesof i nfecti onmay contri bute to t certaintypesof i nfecti onmay contri bute to t
he development of autoimmune (exp he development of autoimmune (exp erimenti n l abani mal ) erimenti n l abani mal )
• potentially dangerous under conditio potentially dangerous under conditio ns of extreme autoimmune sensitivit ns of extreme autoimmune sensitivit
y (inhibit B cell apoptosis by ISS) y (inhibit B cell apoptosis by ISS)
![Page 67: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/67.jpg)
– Reduction in antigen Reduction in antigen expression (induce expression (induce interferon)interferon)•too much ISS may inhibit too much ISS may inhibit immune responseimmune response
![Page 68: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/68.jpg)
• Clinical applications Clinical applications– Allergy (Th 1 response Allergy (Th 1 response
LL L LLLLLL2 LL L LLLLLL2))
– - 2Infectious disease (Th bias i - 2Infectious disease (Th bias i mmune response) mmune response)
![Page 69: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/69.jpg)
Biological adjuvant Biological adjuvantss
• Dendritic cell (DC) Dendritic cell (DC)– establishmentof cell culture (mous establishmentof cell culture (mous
-e spleen &bone marrow GM -e spleen &bone marrow GM -CSFand IL 4 ) -CSFand IL 4 )
– -34CD+(cordblood,bonemarrow,peri pheral bl ood) i nGMC -34CD+(cordblood,bonemarrow,peri pheral bl ood) i nGMCLL LLL LLL-L LL LLL LLL-L
– LLLLL L LLLLLLLL LLLLLLLL LL L L -LLLLLL L LLLLLLLL LLLLLLLL LL L L -L -4SFandI L -4SFandI L
DCDC
![Page 70: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/70.jpg)
– Cancer vaccine Cancer vaccine• Cul turedDCwhenadopti vel y transfe Cul turedDCwhenadopti vel y transfe
rredcaneff ecti vel y present tumor a rredcaneff ecti vel y present tumor anti gennti gen
•- -Genebasedvacci ne VS.pepti de pul sed- -Genebasedvacci ne VS.pepti de pul sed– does not require prior knowledge of patient
- - HLA haplotype or of specific T cell epitope– - -may promote both class I and II restricted T
cell responses
![Page 71: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/71.jpg)
• Vaccination with culture DC ex vi Vaccination with culture DC ex vivovo– viralvector(retrovirus,adenovirus,poxvi rus) viralvector(retrovirus,adenovirus,poxvi rus)– pl asmi dDNA pl asmi dDNA– RNARNA– circumvent the neutralizing antibodies circumvent the neutralizing antibodies
which is the problem ofusing adenoviru which is the problem ofusing adenoviru ses in vivo ses in vivo
![Page 72: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/72.jpg)
Virus vectorsVirus vectors• Retrovirus vector
– express throughout the life of the cell– However,needcellsthat undergone cel l di vi si on(chro
mosomali ntegrati on)– CD34+progeni tor cel l– Transductionefficiency(11.5%cellfrombonemarrow&21.2%fromcordbl ood)
![Page 73: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/73.jpg)
![Page 74: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/74.jpg)
Retrovirus vector MFG, Retrovirus vector MFG, MLV LTR,MLV LTR,
in packaging cellin packaging cell Ecotropic CRE packaging cell line Ecotropic CRE packaging cell line
Ecotropic BOSC23 packaging cell line Ecotropic BOSC23 packaging cell line
Amphotropic CRIP packaging cell line Amphotropic CRIP packaging cell line
Amphotropic BING packaging cell line Amphotropic BING packaging cell line
Amphotropic PA317 packaging cell line Amphotropic PA317 packaging cell line
Amphotropic PG13 packaging cell line Amphotropic PG13 packaging cell line
![Page 75: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/75.jpg)
• - HER 2 (Specht et al., 1997)- HER 2 (Specht et al., 1997)– CTL,prophylactic/therapeuticanti tumor i mmuni ty CTL,prophylactic/therapeuticanti tumor i mmuni ty
• -80Human CD and Murine IL -80Human CD and Murine IL 12 (Nishioka et al., 1997) 12 (Nishioka et al., 1997)
– LLLLLLLLL LLLLLL LL LLLLLLLLLLLLL LLLLLL LL LLLL• - 1Human MUC (Henderson e - 1Human MUC (Henderson e
t al., 1996) t al., 1996)– LLLL LLLLLLLLLLLLLL LLLLLLLLLL
![Page 76: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/76.jpg)
•Human MART-1 (Reeves Human MART-1 (Reeves et al., 1996)et al., 1996)– Gene expression and Gene expression and antigen presentation in antigen presentation in vivovivo
![Page 77: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/77.jpg)
• Adenovi ral vectors Adenovi ral vectors– nondividing cell nondividing cell– transient gene expression transient gene expression– immune response against vir immune response against vir
us itself us itself
• Multiplicity of infection (M.O.I) Multiplicity of infection (M.O.I)– -Adv type (100:1) 1 5% -Adv type (100:1) 1 5%– 10,000 95% 10,000 95%
![Page 78: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/78.jpg)
• Physical method for gene Physical method for gene transfer are relatively ine transfer are relatively ine
fficient (DNA/liposome, el fficient (DNA/liposome, el ectroporation and calciu ectroporation and calciu
m phosphate precipitatio m phosphate precipitation)n)
![Page 79: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/79.jpg)
- - - Adenoviral vector (E1 deleted, replication deficient, Ad 5 vector) - - - Adenoviral vector (E1 deleted, replication deficient, Ad 5 vector) CMV promoter/enhancer CMV promoter/enhancer or or LLLL LLLLLLLLLLLLL/ LLLL LLLLLLLLLLLLL/
40SV poly A termination signal 40SV poly A termination signal
![Page 80: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/80.jpg)
• - - 2 7 1IL and IL (Authur et al.,- - 2 7 1IL and IL (Authur et al.,997)997)– gene expression gene expression
• (. ,1 997) (. ,1 997)– - CTL and anti tumor immunity - CTL and anti tumor immunity
• - 1( . ,1 997)- 1( . ,1 997)– - CTL and anti tumor immunity - CTL and anti tumor immunity
![Page 81: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/81.jpg)
• Polyoma middle T antige Polyoma middle T antige n (Wan et al., 1997) n (Wan et al., 1997)
– - CTL and anti tumor immunity - CTL and anti tumor immunity
![Page 82: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/82.jpg)
• Naked DNA Naked DNA– can transfection more than can transfection more than
one gene (immunostimulat one gene (immunostimulat ory cytokine) ory cytokine)
– without immunological inte without immunological inte rference from viral protein rference from viral protein
– no risk of recombination no risk of recombination
![Page 83: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/83.jpg)
– No insertion of foreign DNA in No insertion of foreign DNA in to the genome to the genome
– can readily be produced in lar can readily be produced in larLL LLLLLLLLLL LLL LLLLLLLL LLLLLLLLLL LLL LLLLLL
– lower transduction efficiency lower transduction efficiency butstill can induce CTL butstill can induce CTL
![Page 84: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/84.jpg)
![Page 85: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/85.jpg)
Plasmid construction Plasmid construction
![Page 86: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/86.jpg)
• 1995Humantyrosinase(melanoma) (Alijagicetal., ) 1995Humantyrosinase(melanoma) (Alijagicetal., )• - - 1 17 1MART /Melan A, pmel /gp- - 1 17 1MART /Melan A, pmel /gp
- - 00, , 1 3 ( ., 1998)tyrosinaseMAGE andMAGE Tutingetal - - 00, , 1 3 ( ., 1998)tyrosinaseMAGE andMAGE Tutingetal• - LLL1 6 7 5 3 ( .- LLL1 6 7 5 3 ( .
1997, ) 1997, )• - 1 1997HSV gB (Manickan et al.,- 1 1997HSV gB (Manickan et al.,
))anmlcancer.htm
![Page 87: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/87.jpg)
AdjuvantAdjuvant
![Page 88: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/88.jpg)
• Adjuvants for plasmid DN Adjuvants for plasmid DN A vaccines A vaccines
– Bupivacaine (myotoxin) Bupivacaine (myotoxin)– Polyvinyl pyrollidone (PVP) Polyvinyl pyrollidone (PVP)– Neutral, anionic and cationic l Neutral, anionic and cationic l
LLLLLLLL
![Page 89: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/89.jpg)
•BupivacaineBupivacaine– destroys myofi ber cel l macroph destroys myofi ber cel l macroph
ages cl earance of debri s prol i f ages cl earance of debri s prol i f erati onof muscl e precursor cel l s erati onof muscl e precursor cel l s
– -enhancementonly occurs with a low effi -enhancementonly occurs with a low effi- ciency expressing plasmid- ciency expressing plasmid
– - better to use high expressing naked DN - better to use high expressing naked DN A(CMVpromotor) rather than use bupiv A(CMVpromotor) rather than use bupiv
acaineacaine
![Page 90: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/90.jpg)
• Polyvinylpyrollidone(PVP) & DMRI E:DOPE cat i oni c l i pi d Polyvinylpyrollidone(PVP) & DMRI E:DOPE cat i oni c l i pi d– Controversy (increase or decrease exp Controversy (increase or decrease expression)ression)
• DMRIE:DOPE (enhance immune r DMRIE:DOPE (enhance immune r esponse, decrease transgene ex esponse, decrease transgene ex
L LL LL LLL LL LLLL LL L) L LL LL LLL LL LLLL LL L) elease plasmid DNA for uptake b elease plasmid DNA for uptake b
L L LLLLL LLL LLLLLLL LLLLLL L LLLL L LLLLL LLL LLLLLLL LLLLLL L LLLLLLL
![Page 91: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/91.jpg)
![Page 92: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/92.jpg)
![Page 93: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/93.jpg)
![Page 94: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/94.jpg)
![Page 95: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/95.jpg)
![Page 96: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/96.jpg)
![Page 97: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/97.jpg)
anmlalrgy.htm
DNA vaccine for human medicineDNA vaccine for human medicine
![Page 98: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/98.jpg)
DNA vaccine for DNA vaccine for Veterinary UseVeterinary Use
![Page 99: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/99.jpg)
![Page 100: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/100.jpg)
![Page 101: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/101.jpg)
![Page 102: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/102.jpg)
BiopharmaceuticBiopharmaceutical farmingal farming
![Page 103: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/103.jpg)
Biopharmaceutical Biopharmaceutical farmingfarming
• Transgeni c ani mal Transgeni c ani mal• Edible vaccine and biologica Edible vaccine and biologica
l products l products– Transgenic plants Transgenic plants– Chimeric plant virus Chimeric plant virus
![Page 104: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/104.jpg)
Transgenic anima Transgenic animall
![Page 105: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/105.jpg)
ObjectivesObjectives• Economically important trait i Economically important trait i
mprovementmprovement– -Porcine growth hormone hMt pGH -Porcine growth hormone hMt pGH– - -Sheepkerati n I GF I - -Sheepkerati n I GF I
•BiomedicineBiomedicine– Pharmaceuti cal Protei ns Pharmaceuti cal Protei ns– L( L( hDAFdecay accelerating factor &hC hDAFdecay accelerating factor &hC
D5 9 transgenic pig D5 9 transgenic pig ) )– Recombi nant anti bodi es Recombi nant anti bodi es
![Page 106: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/106.jpg)
![Page 107: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/107.jpg)
Strategies for Strategies for delivery genedelivery gene
• Microinjection Microinjection– - 01Fertilized embryo [( . %) in cattle ( - 01Fertilized embryo [( . %) in cattle (
5 % ) in mice 5 % ) in mice– LL LLLLL LL LLLLLL LLLLLLLL ( ) LL LLLLL LL LLLLLL LLLLLLLL ( )
LLL LLLLLLLLLLLL LLLLLLLLL• Nuclear transfer Nuclear transfer 1(Schnieke et al., 1(Schnieke et al.,
BBBB9 9 7 ; . , 1 9 9 8 ; BBBB9 9 7 ; . , 1 9 9 8 ; 1999isi et al., ) 1999isi et al., )
– embryonic stem cell (ES, EG, EC) embryonic stem cell (ES, EG, EC)– somatic cell (cattle, sheep, goat, pig) somatic cell (cattle, sheep, goat, pig)
![Page 108: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/108.jpg)
• Sperm mediated DNA transfer Sperm mediated DNA transfer (( 1998 19Gandolfi, ; Squires, 1998 19Gandolfi, ; Squires,
9999
• Intracytoplasmic injection ICSI Intracytoplasmic injection ICSI of transgenic sperm heads of transgenic sperm heads (Perryetal., 19 (Perryetal., 1999)99)
• Retroviral vectors either by inje Retroviral vectors either by inje ction or infection of oocytes or ction or infection of oocytes or
embryos embryos (HaskellandBowen, 1995; Chanetal., 1998) (HaskellandBowen, 1995; Chanetal., 1998)
![Page 109: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/109.jpg)
![Page 110: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/110.jpg)
![Page 111: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/111.jpg)
Nuclear transferNuclear transfer : : Somatic cell (fibroblast)Somatic cell (fibroblast)
![Page 112: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/112.jpg)
![Page 113: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/113.jpg)
![Page 114: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/114.jpg)
![Page 115: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/115.jpg)
![Page 116: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/116.jpg)
Control of gene Control of gene expressionexpression
• Induciblegene(metallothioneinpromoter,heatshock promoter,steroi d Induciblegene(metallothioneinpromoter,heatshock promoter,steroi d responsive elements, tetracycl responsive elements, tetracycl
ine regulatable system) ine regulatable system)• I nternal ri bosome entry si t I nternal ri bosome entry si t
es I RESanddi ci stroni c RNAs es I RESanddi ci stroni c RNAs• Artificialchromosomes(YAC,MAC) Artificialchromosomes(YAC,MAC)
![Page 117: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/117.jpg)
Mammary specific Mammary specific regulatory regulatory sequencesequence• Murine whey acid protein Murine whey acid protein
(WAP)(WAP)• -Bovine alpha lactalbumin -Bovine alpha lactalbumin• - -Bovine alpha s1 casein - -Bovine alpha s1 casein• -Ovi ne beta l actogl obul i n -Ovi ne beta l actogl obul i n• -Caprine beta casein -Caprine beta casein
![Page 118: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/118.jpg)
-(Alpha glucosidase)-(Alpha glucosidase)
![Page 119: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/119.jpg)
Species selectionSpecies selection
Transgenic mice is an ideal system to test expression constructs: mammal milk Transgenic mice is an ideal system to test expression constructs: mammal milk promotor sequences capable of expression in mouse promotor sequences capable of expression in mouse
![Page 120: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/120.jpg)
![Page 121: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/121.jpg)
![Page 122: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/122.jpg)
Cost of transgenic a Cost of transgenic a nimal production nimal production
• 12One transgenic mouse (~ US$ 12One transgenic mouse (~ US$ 0) 0)
• 250One transgenic pig (~ US$ , 250One transgenic pig (~ US$ ,00)00)
• ( ~ 6 0 , ( ~ 6 0 ,000)000)
• ( ~ 5 4 6 , ( ~ 5 4 6 ,000)000)
Wall et al., 1992Wall et al., 1992
![Page 123: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/123.jpg)
![Page 124: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/124.jpg)
![Page 125: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/125.jpg)
AnticoagulantAnticoagulant
inactivating factors V inactivating factors Vaa & VIII & VIIIaa
PACE (paired basic amino acid PACE (paired basic amino acid - cleaving enzyme) = subtilisin like - cleaving enzyme) = subtilisin like
serine protease furin serine protease furin
Bigenic mouse
![Page 126: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/126.jpg)
Production of antibodiesProduction of antibodies
![Page 127: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/127.jpg)
![Page 128: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/128.jpg)
![Page 129: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/129.jpg)
![Page 130: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/130.jpg)
Purification of Purification of recombinant recombinant
proteinprotein•Standard dairy procedure (for Standard dairy procedure (for antibody)antibody)– casein-free, fat-free and lactose-free casein-free, fat-free and lactose-free protein concentrate (30-60% purity)protein concentrate (30-60% purity)
– ion exchange chromatography, ion exchange chromatography, hydrophobic interaction hydrophobic interaction chromatography and affinity chromatography and affinity chromatography (Protein A or chromatography (Protein A or Protein G)Protein G)
![Page 131: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/131.jpg)
![Page 132: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/132.jpg)
Transgenic plant Transgenic plant
![Page 133: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/133.jpg)
Trangenic plant Trangenic plant
•Cholera vaccineCholera vaccine•HBV, FMDV, Norwalk HBV, FMDV, Norwalk
virus, RSV, TGEV, Rabies virus, RSV, TGEV, Rabies virus, PRRSVvirus, PRRSV
![Page 134: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/134.jpg)
![Page 135: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/135.jpg)
![Page 136: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/136.jpg)
![Page 137: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/137.jpg)
![Page 138: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/138.jpg)
![Page 139: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/139.jpg)
FMDVFMDV
![Page 140: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/140.jpg)
Chimeric plant virus Chimeric plant virus
•VaccineVaccine– - 141HIV gp , Rabiesvirus, HCV, Cani ne par vovi r us- 141HIV gp , Rabiesvirus, HCV, Cani ne par vovi r us– S. aureus S. aureus , , P. aeruginosa P. aeruginosa
• Monoclonal antibody producti Monoclonal antibody productionon– - - -171 7332CO A(againstcolorectalcancerassociatedantigenGA )- - -171 7332CO A(againstcolorectalcancerassociatedantigenGA )– LLLLLL LLLLLLLLLLL LLLLL
![Page 141: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/141.jpg)
Chimeric plant virus Chimeric plant virus
• TMV(Tobaccomosai c vi rus) TMV(Tobaccomosai c vi rus)• CPMV(Cowpeamosai c vi rus) CPMV(Cowpeamosai c vi rus)• AlMV(Alfalfa mosaic virus) AlMV(Alfalfa mosaic virus)• PPV(Plum poty virus) PPV(Plum poty virus)
![Page 142: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/142.jpg)
HCVHCV
![Page 143: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/143.jpg)
HIV V3 HIV V3 looploop
Rabies virusRabies virus
![Page 144: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/144.jpg)
Outer membrane F protein Outer membrane F protein of of P. aeruginosa P. aeruginosa
![Page 145: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/145.jpg)
![Page 146: DNA vaccine and Biopharmaceutical protein Production](https://reader035.vdocuments.site/reader035/viewer/2022062322/568144d4550346895db19fcb/html5/thumbnails/146.jpg)